FDA Quietly Retires 34 Forgotten Medicines
Published Date: 7/6/2026
Notice
Summary
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
34 Drug Approvals Withdrawn Aug 5, 2026
The FDA is withdrawing approval of 34 new drug applications (NDAs) as of August 5, 2026. After that date, introducing the listed products into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act.
On‑hand Inventory Can Still Be Dispensed
Drug products listed in the withdrawal may continue to be dispensed from existing inventory until those inventories are depleted, the products reach their expiration dates, or they otherwise become violative. This temporary allowance applies starting August 5, 2026.
Companies Waived Hearings; Can Refile
Applicants voluntarily requested withdrawal and waived their opportunity for a hearing; withdrawal under 21 CFR 314.150(c) is without prejudice to refiling, so companies may reapply for approval of these drugs in the future.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-13615, Draft Guidance for Reducing Risk From Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonic Acid (PFOS) in Biosolids; Establishment of a Public Docket; Request for Feedback
The EPA is sharing a draft guide to help wastewater plants, farmers, and water agencies reduce harmful chemicals called PFOA and PFOS in biosolids (treated sewage sludge). They want your thoughts on these ideas by September 4, 2026. While this guide isn’t a rule yet, it’s a big step toward safer soil and water, with no immediate costs but plenty of future benefits.
Next: 2026-13617, New Postal Products
The Postal Service has asked for approval of new or changed special deals for competitive mail services. This affects businesses using these services and could change prices or options soon. Everyone has until July 8, 2026, to share their thoughts before the Postal Regulatory Commission makes a decision.